Repaglinide, a rapidly acting insulin secretagog, stimulates insulin secretion via closure of ATP-dependent potassium channels on the cell membrane of β-cells. Repaglinide is ideally used at ...

Repaglinide, an insulin secretagog, and metformin, an insulin sensitizer, targets two different pathophysiological mechanisms underlying Type 2 diabetes, namely reduced insulin secretion and ...